sprycel 20 mg
bristol, myers squibb (israel) limited, israel - dasatinib - film coated tablets - dasatinib 20 mg - dasatinib - treatment of adult patients with : * newly diagnosed philadelphia chromosome positive (ph+) chronic myelogenous leukaemia (cml) in the chronic phase. * chronic, accelerated or blast phase cml with resistance or intolerance to prior therapy including imatinib mesilate. * ph+ acute lymphoblastic leukaemia (all) and lymphoid blast cml with resistance or intolerance to prior therapy.
sprycel 50 mg
bristol, myers squibb (israel) limited, israel - dasatinib - film coated tablets - dasatinib 50 mg - dasatinib - treatment of adult patients with : * newly diagnosed philadelphia chromosome positive (ph+) chronic myelogenous leukaemia (cml) in the chronic phase. * chronic, accelerated or blast phase cml with resistance or intolerance to prior therapy including imatinib mesilate. * ph+ acute lymphoblastic leukaemia (all) and lymphoid blast cml with resistance or intolerance to prior therapy.
sprycel 70 mg
bristol, myers squibb (israel) limited, israel - dasatinib - film coated tablets - dasatinib 70 mg - dasatinib - treatment of adult patients with : * newly diagnosed philadelphia chromosome positive (ph+) chronic myelogenous leukaemia (cml) in the chronic phase. * chronic, accelerated or blast phase cml with resistance or intolerance to prior therapy including imatinib mesilate. * ph+ acute lymphoblastic leukaemia (all) and lymphoid blast cml with resistance or intolerance to prior therapy.
nivolumab bms concentrate for solution for infusion 10mgml
bristol-myers squibb (singapore) pte. ltd. - nivolumab - infusion, solution concentrate - nivolumab 10 mg/ml
sprycel 100 mg
bristol, myers squibb (israel) limited, israel - dasatinib - film coated tablets - dasatinib 100 mg - dasatinib - treatment of adult patients with : * newly diagnosed philadelphia chromosome positive (ph+) chronic myelogenous leukaemia (cml) in the chronic phase. * chronic, accelerated or blast phase cml with resistance or intolerance to prior therapy including imatinib mesilate. * ph+ acute lymphoblastic leukaemia (all) and lymphoid blast cml with resistance or intolerance to prior therapy.
sprycel 20 mg
bristol, myers squibb (israel) limited, israel - dasatinib - film coated tablets - dasatinib 20 mg - dasatinib - treatment of adult patients with : * newly diagnosed philadelphia chromosome positive (ph+) chronic myelogenous leukaemia (cml) in the chronic phase. * chronic, accelerated or blast phase cml with resistance or intolerance to prior therapy including imatinib mesilate. * ph+ acute lymphoblastic leukaemia (all) and lymphoid blast cml with resistance or intolerance to prior therapy.
sprycel 50 mg
bristol, myers squibb (israel) limited, israel - dasatinib - film coated tablets - dasatinib 50 mg - dasatinib - treatment of adult patients with : * newly diagnosed philadelphia chromosome positive (ph+) chronic myelogenous leukaemia (cml) in the chronic phase. * chronic, accelerated or blast phase cml with resistance or intolerance to prior therapy including imatinib mesilate. * ph+ acute lymphoblastic leukaemia (all) and lymphoid blast cml with resistance or intolerance to prior therapy.
sprycel 70 mg
bristol, myers squibb (israel) limited, israel - dasatinib - film coated tablets - dasatinib 70 mg - dasatinib - treatment of adult patients with : * newly diagnosed philadelphia chromosome positive (ph+) chronic myelogenous leukaemia (cml) in the chronic phase. * chronic, accelerated or blast phase cml with resistance or intolerance to prior therapy including imatinib mesilate. * ph+ acute lymphoblastic leukaemia (all) and lymphoid blast cml with resistance or intolerance to prior therapy.
inrebic
bristol, myers squibb (israel) limited, israel - fedratinib as dihydrochloride monohydrate - capsules - fedratinib as dihydrochloride monohydrate 100 mg - fedratinib - inrebic® is indicated for the treatment of adult patients with intermediate-2 or high-risk primary or secondary (post-polycythemia vera or post-essential thrombocythemia) myelofibrosis (mf)
opdualag
bristol, myers squibb (israel) limited, israel - nivolumab; relatlimab - concentrate for solution for infusion - relatlimab 4 mg/ml; nivolumab 12 mg/ml - nivolumab - opdualag is indicated for the treatment of adult and pediatric patients 12 years of age or older with unresectable or metastatic melanoma.